Patents by Inventor Sunita R. Hett

Sunita R. Hett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TISSUE FACTOR PATHWAY INHIBITOR ANTIBODIES AND USES THEREOF
    Publication number: 20250145732
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Application
    Filed: November 5, 2024
    Publication date: May 8, 2025
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • Tissue factor pathway inhibitor antibodies and uses thereof
    Patent number: 12168698
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Grant
    Filed: March 13, 2023
    Date of Patent: December 17, 2024
    Assignee: Pfizer Inc.
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • TISSUE FACTOR PATHWAY INHIBITOR ANTIBODIES AND USES THEREOF
    Publication number: 20230416405
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Application
    Filed: March 13, 2023
    Publication date: December 28, 2023
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • Tissue factor pathway inhibitor antibodies and uses thereof
    Patent number: 11634504
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: April 25, 2023
    Assignee: Pfizer Inc.
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • NOVEL ANUCLEATED CELLS AND USES THEREOF
    Publication number: 20220143095
    Abstract: Disclosed herein are non-naturally existing novel platelet variants or platelet like cells (PLCs), extracellular vesicles (EVs), and derivatives thereof. Composition comprising the same and methods for treatment or prevention of diseases or disorders therewith is also disclosed.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 12, 2022
    Inventors: Sunita R. Hett, Karen Weisinger, Yang Peng, Kyle P. McLaughlin, Christian G. Peters, Andrew R. Zukauskas, Brenden W. Smith, Silvia Giannini, Marcus Lehmann
  • ANUCLEATED CELLS FOR THE TREATMENT OF DISEASES
    Publication number: 20210299181
    Abstract: The present disclosure takes advantage of non-naturally existing, novel, anucleated platelets or platelet-like cells or platelet variants (collectively referred to as PLCs) or derivatives thereof (i.e., genetically engineered), which share at least one common receptor, ligand or an antigen with endogenous cells that are targets for autoantibodies and effectuate their clearance. The present disclosure also takes advantage of viral adhesion or entry receptors or genetically engineered PLCs or derivatives thereof, which are engineered to express viral adhesion or entry receptors, that specifically binds to viral proteins on viruses or viral particles and effectuate their clearance.
    Type: Application
    Filed: March 26, 2021
    Publication date: September 30, 2021
    Inventors: Sunita R. Hett, Karen Weisinger, Yang Peng, Kyle P. McLaughlin, Christian G. Peters, Andrew R. Zukauskas, Brenden W. Smith, Silvia Giannini, Po-Shun Lee
  • NOVEL ANUCLEATED CELLS AND USES THEREOF
    Publication number: 20210299180
    Abstract: Disclosed herein are non-naturally existing novel platelet variants or platelet like cells (PLCs), extracellular vesicles (EVs), and derivatives thereof. Composition comprising the same and methods for treatment or prevention of diseases or disorders therewith is also disclosed.
    Type: Application
    Filed: March 26, 2021
    Publication date: September 30, 2021
    Inventors: Sunita R. Hett, Karen Weisinger, Yang Peng, Kyle P. McLaughlin, Christian G. Peters, Andrew R. Zukauskas, Brenden W. Smith, Silvia Giannini, Marcus Lehmann
  • TISSUE FACTOR PATHWAY INHIBITOR ANTIBODIES AND USES THEREOF
    Publication number: 20210101998
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Application
    Filed: November 24, 2020
    Publication date: April 8, 2021
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • Tissue factor pathway inhibitor antibodies and uses thereof
    Patent number: 10875929
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: December 29, 2020
    Assignee: Pfizer Inc.
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • TISSUE FACTOR PATHWAY INHIBITOR ANTIBODIES AND USES THEREOF
    Publication number: 20200190214
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Application
    Filed: December 17, 2019
    Publication date: June 18, 2020
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • Tissue factor pathway inhibitor antibodies and uses thereof
    Patent number: 10550200
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: February 4, 2020
    Assignee: Pfizer Inc.
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • TISSUE FACTOR PATHWAY INHIBITOR ANTIBODIES AND USES THEREOF
    Publication number: 20170073428
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Application
    Filed: August 17, 2016
    Publication date: March 16, 2017
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja